arrow
返回
G

Gerald S. Falchook

Sarah Cannon Research Institute

68H指数
810论文数
2.7W被引数
收录论文 168
发表时间
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerAZD2811在复发/难治性小细胞肺癌的I期剂量扩展研究中通过生物标志物分析进行疗效监测
err2026-04-03
err0
errOAAI
errMelissa L. Johnson; Giulia Fabbri; Carmela Ciardullo; Judy S. Wang; Gerald S. Falchook; Suzanne Jones; Donald Strickland; Jacob Sands; Carl M. Gay; Robert J. Cardnell; Luis Tobalina; Sophie E. Willis; Jaime Rodriguez-Canales; Myria Nikolaou; Emma V. Jones; Stein Schalkwijk; Liz Sainsbury; Alexander MacDonald; Philip Overend; Caroline Kennedy; J. Elizabeth Pease; Philip Szekeres; Jan Cosaert; Howard Burris; Lauren A. Byers
err分享
err收藏
Ifinatamab deruxtecan, a B7-H3-directed antibody–drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trialIfinatamab deruxtecan,一种B7-H3靶向抗体—药物偶联物,在晚期实体瘤患者中的研究(IDeate-PanTumor01):一项1/2期试验的剂量递增结果
err2026-03-30
err0
PREAI
errMelissa L Johnson; Manish R Patel; Gerald S Falchook; Takafumi Koyama; Martin Gutierrez; Mark M Awad; Sarina A Piha-Paul; Claire F Friedman; Taroh Satoh; Naoko Okamoto; Jasmeet Singh; Naoto Yoshizuka; Hillarie Plessner Windish; Meng Qian; Brittany P Tran; Toshihiko Doi
err分享
err收藏
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors一项关于SHP2抑制剂BBP-398在晚期实体瘤患者中的首次人体I期研究
err2026-02-28
err0
errOAAI
errGerald Falchook; Camila Braganca Xavier; David Van Veenhuyzen; Jyoti Malhotra; Saeed Sadeghi; Arash Rezazadeh Kalebasty; Lauren Wood; Faisal Rahman; Elizabeth Li; Yvonne Pak; Maya Khalil; Alexander I. Spira; David Sommerhalder; Ignacio Garrido-Laguna; David S. Hong
err分享
err收藏
AXL Inhibitors in Oncology Clinical Trials: A Review肿瘤学临床试验中的AXL抑制剂:综述
err2026-02-01
err0
PREAI
errQuach, Ethan; Sanginova, Farahnoz; Cheruku, Anish; Stack, Sophia; Falchook, Gerald S.
err分享
err收藏
Phase 1b and Dose-Expansion Study of GSK3326595, a PRMT5 Inhibitor as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced CancersGSK3326595的1b期和剂量扩展研究,PRMT5抑制剂作为单一疗法并与Pembrolizumab联合用于晚期癌症患者
err2025-09-09
err0
PREAI
errM.M. Gounder; P. Martin-Romano; A. Italiano; L.L. Siu; P.A. Cassier; G.S. Falchook; I.S. Lossos; D.W. Rasco; J.F. Hilton; M.A. McKean; F.L. Opdam; J. Strauss; M. De Jonge; J.S.P. Vermaat; T. Crossman; M. Zajac; A. Tarkar; F. Gonzalez Carreras; B.E. Kremer; O. Barbash; S. Segal; R. Parasrampuria; S. Postel-Vinay
err分享
err收藏
Safety, Tumor Homing And Immune Effects Of Systemically Administered Vocimagene Amiretrorepvec In Patients With Advanced Solid Tumors: A Phase 1B Study安全性、肿瘤归巢及免疫效应:系统性给予vocimagene amiretrorepvec治疗晚期实体瘤患者的1B期研究
err2025-08-21
err0
errOAAI
errJaime R. Merchan; Jordi Rodon; Shree Venkat; Arthur Donahue; Amber Thomassen; William P. Accomando; Maria Rodriguez-Aguirre; Deukwoo Kwon; Cornelia Bentley; Daniel J. Hogan; Olivia Roos Rodrigues; Sharon Yavrom; Derek Ostertag; Jolene Shorr; Gerald S. Falchook
err分享
err收藏
A novel approach for first-in-human dose selection using population dose-response modelling to find a minimum anticipated biological effect level一种利用群体剂量-反应模型确定最小预期生物效应水平,以进行首次人体试验剂量选择的新方法
err2025-04-27
err0
PREAI
errLin Yuan; Meghana Kulkarni; Evan Chiswick; Cheryl Koh; Peter Sandy; Salah Nabhan; Woody Sherman; Melissa Johnson; Judy Wang; Gerald Falchook; Jennifer Johnson; Christopher Winter; Humphrey Gardner; Arijit Chakravarty; Madison Stoddard
err分享
err收藏
A phase Ib study evaluating the c-MET inhibitor INC280 (capmatinib) in combination with bevacizumab in patients with high-grade glioma
err2024-12-11
err0
errOAAI
errFalchook, Gerald S.; Battiste, James D.; Kalra, Amandeep; Shastry, Mythili; Finney, Lindsey; Hoekstra, Susan J.; Shih, Meredith G.; Shih, Kent C.
err分享
err收藏
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors
err2024-11-19
err0
errOAAI
errPatel, Manish R.; Falchook, Gerald S.; Wang, Judy S.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Miah, Kowser; Mugundu, Ganesh M.; Jones, Suzanne F.; Spigel, David R.; Hamilton, Erika P.
err分享
err收藏
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial
err2024-11-01
err1
errOAAI
errHamilton, Erika P.; Falchook, Gerald S.; Wang, Judy S.; Fu, Siqing; Oza, Amit M.; Imedio, Esteban Rodrigo; Kumar, Sanjeev; Ottesen, Lone; Mugundu, Ganesh M.; de Bruin, Elza C.; O'Connor, Mark J.; Jones, Suzanne F.; Spigel, David R.; Li, Bob T.
err分享
err收藏
Results from a phase 1/2, first-in-human, dose escalation and dose expansion study of an investigational anti-ADAM9 antibody-drug conjugate IMGC936 in patients with advanced solid tumors
err2024-10-01
err0
PREAI
errSubbiah, V.; Falchook, G.; Davis, A. A.; Wang, J. S.; de Miguel, M.; Santoro, A.; Maur, M.; Aljumaily, R.; Boni, V.; de Speville, B. Doger; Sun, Y.; Du, Y.; Lakshmikanthan, S.; Bedse, G.; Ward, A.; Zweidler-McKay, P.; Gandhi, L.
err分享
err收藏
Clinical and biomarker data from a phase 1/2 trial of ifinatamab deruxtecan (I-DXd; DS-7300) in advanced solid tumors
err2024-10-01
err0
PREAI
errDoi, T.; Patel, M. R.; Koyama, T.; Falchook, G. S.; Friedman, C.; Piha-Paul, S. A.; Gutierrez, M.; Awad, M.; Mattour, A.; Satoh, T.; Takahashi, S.; Tsunoda, T.; Kadowaki, S.; Watanabe, Y.; Okamoto, N.; Goto, H.; Yoshizuka, N.; Qian, M.; Qian, X.; Johnson, M.
err分享
err收藏
Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced/ metastatic solid tumors: Data from phase I dose escalationDazostinag (TAK-676) 单药及联合 pembrolizumab (pembro) 治疗 advanced/metastatic solid tumors 患者(pts)的疗效:来自 phase I dose escalation 研究的数据
err2024-09-01
err1
PREAI
errLuke, J. J.; Gao, X.; Olszanski, A. J.; Sanborn, R. E.; Falchook, G. S.; Patel, S.; Bedard, P. L.; Orr, D.; Gibbs, J. P.; Li, C.; Huang, Y-C.; Gregory, R.; Ramesh, R.; Xu, R.; Wu, B.; Ding, K.; Raizer, J.; Lorusso, P.
err分享
err收藏
First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors首次人体I期试验:评估溶瘤单纯疱疹病毒ONCR-177单药或联合帕博利珠单抗治疗晚期实体瘤的效果
err2024-09-01
err0
PREAI
errGaspar, C. Fava; Park, J. C.; Falchook, G. S.; Wesolowski, R.; Soliman, H.; Ott, P. A.; Bilen, M. A.; Mckean, M.; Villaflor, V.; Chow, L. Q. M.; Yanez, A.; Dupont, C.; Shepherd, J.; Cheema, T.; Goldberg, J. M.; Puzanov, I.; Spreafico, A.
err分享
err收藏
NKT2152, a novel oral HIF-2α inhibitor, in participants (pts) with previously treated advanced clear cell renal carcinoma (accRCC): Preliminary results of a phase I/II studyNKT2152,一种新型的口服HIF-2α抑制剂,在既往接受过治疗的晚期透明细胞肾癌(accRCC)患者(pts)中的初步结果:一项I/II期研究
err2024-09-01
err2
PREAI
errJonasch, E.; McGregor, B. A.; Msaouel, P.; Logan, T.; Hall, E. T.; Bilen, M. A.; Falchook, G. S.; Shuch, B.; Zakharia, Y.; Hauke, R.; Gordon, M.; Naqash, A-R.; Ryan, C. W.; Srinivasan, R.; Xiao, J.; Sun, W.; Esguerra, M.; Lu, G.; Lager, J.; Choueiri, T. K.
err分享
err收藏
A Relative Bioavailability, Bioequivalence, and Food Effect Study of Niraparib Tablets in Patients with Advanced Solid Tumors尼拉帕尼片在晚期实体瘤患者中的相对生物利用度,生物等效性和食物效应研究
err2024-03-01
err0
errOAAI
errFalchook, Gerald; Patnaik, Amita; Richardson, Debra L.; Harvey, R. Donald; Sharma, Manish R.; Hafez, Navid; Hamilton, Erika; Piha-Paul, Sarina A.; Barve, Minal; Wise-Draper, Trisha; Patel, Manish R.; Dowlati, Afshin; Pascuzzo, Joseph; Tang, Shou-Ching; Faltermeier, Christina; Malinowska, Izabela A.; Shtessel, Luda; Striha, Alina; Potocka, Elizabeth
err分享
err收藏
Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer
err2023-12-01
err1
PREAI
errSwisher, Elizabeth; Falchook, Gerald Steven; Munster, Pamela N.; Bed, Nina; Moore, Kathleen N.; Yap, Timothy A.; Spigel, David R.; Doleman, Susan; Bradley, William D.; O'Shea, Thomas J.; Renschler, Markus F.; Lynch, Ryan C.
err分享
err收藏
Clinical and biological activity of ST101, a peptide antagonist of C/EBPβ, in recurrent Glioblastoma (rGBM) patients. Results from the rGBM cohort of a multi-cohort Phase 2 Study
err2023-12-01
err0
PREAI
errIwamoto, Fabio; Buerki, Robin; Butowski, Nicholas; Peters, Katherine B.; Williams, Anja; Falchook, Gerald; Rotolo, Jim; Michel, Rob; Kaesshaefer, Stephen; Scuoppo, Claudio; Vainstein-Haras, Abi
err分享
err收藏
Pharmacokinetics and pharmacodynamics of IGM-8444, a first-in-class engineered pentameric DR5-targeting agonist IgM monoclonal antibody, in patients with R/R and newly diagnosed cancers
err2023-12-01
err0
PREAI
errHernandez, Genevive; Bilic, Sanela; Guan, Yinghui; So, John; Bhattacharya, Sabya; Wang, Beatrice; Kotturi, Maya; Oyasu, Miho; Desbois, Melanie; Cao, Yuan; Humke, Eric; Ahern, Sean; Sinclair, Angus; Ulahannan, Susanna; Subbiah, Vivek; Pelster, Merideth; Lorusso, Patricia; Falchook, Gerald; Wang, Judy; Barve, Minal; Grewal, Jaspreet; Chow, Warren; Henry, Jason; Cecchini, Michael; Takimoto, Chris; Leabman, Maya
err分享
err收藏
A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
err2023-12-01
err1
PREAI
errUlahannan, Susanna; Pelster, Meredith; LoRusso, Patricia; Falchook, Gerald; Wang, Judy; Barve, Minal; Grewal, Jaspreet; Chow, Warren; Henry, Jason; Cecchini, Michael; Subbiah, Vivek; Leabman, Maya; Hernandez, Genevive; Li, Yao; Sinclair, Angus; Wang, Beatrice; Kotturi, Maya; Humke, Eric; Ahern, Sean; Ennis, Leslie; Caruano, Melaine; Agrawal, Sapeck
err分享
err收藏